US FDA issues draft guidance for evaluating cardiovascular safety of new medicines for type 2 diabetes

The FDA proposes safety evaluations before drug approval that look beyond ischaemic CVD, as well as for the inclusion of a broader scope of participants ie older subjects and those with chronic kidney disease who may be more vulnerable to drug-related side effects.


US Food and Drug Administration